Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Last I heard they do have $ for studies into next year but don't have cash to start the Hypertension clinical trials so I would think by mid-October they'll need to raise $. Not sure about amounts tho. One big green flag I see is Invenomic Capital Management has been heavily accumulating shares and now owns almost 10% of the commons. IMO they aren't going to be letting this drop off the Nasdaq when they can just keep adding at a buck or as long for as long as someone keeps selling them shares. Hopefully you're right about pairing the IND with a raise in a positive way. Hopefully this is bottom.
LEXX needs more money for clinical trials whether they do a RS or not so there will be dilution either way. If there is dilution at a buck then the price will drop to below a buck accordingly. It makes more sense to do an RS to at least stay in compliance. Say we get diluted to $0.50 because of a raise. Isn't it better to be still above the buck compliance with say a 6:1 to put us at $3 bucks and give us some breathing room? That makes sense to me even though the dilution sucks.
I do get the feeling though that Bunka and the bigger holders will force the RS through anyway.
How does voting no on the RS help new shareholders? Please elaborate how getting delisted could benefit shareholders. Thanks.
More deals sounds good to me. Especially large ones with big tobacco or pharma please.
Did you forget about the huge deal we made this summer with Premier in Japan?
"In order to retain ongoing exclusivity, the negotiated minimum quarterly payments ("Payments") to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to US$4,527,500. Assuming that Premier continues to submit all required payments, the license for the Japanese market is perpetual.
In addition to the Payments, Lexaria will also receive royalty revenue from DehydraTECH licensed product sales, the terms of which have been agreed to. Total revenue is expected to be significantly greater than the minimum Payments if Premier is capable of meeting its expected revenue targets. If Premier achieves even their worst-case projected penetration into the Japanese non-pharmaceutical CBD market, then based on their projections Lexaria could expect to receive annual payments of over $5 million by the fifth year of the contract".
This money will pay quite a few bills going forward and I'm sure Chris is working hard on more deals as we speak.
It is when CBD by itself isn't doing the job required of it. Also, if JAZZ could easily run trials for additional uses then why haven't they? Possibly because plain old CBD isn't bio-available enough??
Check this out from Dilly at CEO_ca. Mega You-tuber "Whistlin' Diesel" is advertising Cannadips in this video from yesterday that already has over a million views. See ad just after 2.5 minutes :).
Perfectly put. Thanks Shawking.
Good thing we have honest folk like yourself just cruising the stock boards to help out all the stupid traders that are losing all their money. Appreciate it...LOL.
Jazz couldn't run a trial with DehydraTECH because they haven't bought it yet. CBD is made more bio-available with DehydraTECH to the point that it can make lipophylic drugs and cannabinoids that aren't quite good enough viable and it can make drugs that are useful better.
Strange how you conveniently missed the most important news that LEXX will be issuing in the next couple of weeks as per Bunka's update posted by Shawking a couple of days ago:
Hypertension study Hyper-H21-4 - "Hypertension results are a bit slow in coming from the clinicians in part due to the sheer volume of work. But it is starting to arrive (finally) and we should have initial results to report in the next two weeks or maybe even less."
but hey, go ahead and sell all your shares as you suggest, lol ;)
Did we lose out? That's a question that is redundant and will never be answered. One could argue IQOS is competition like a truck is competition for a car but Heat not Burn devices are not oral nicotine or pouches or patches. Lexaria's nicotine products are also designed to help smokers and vapers move to a less harmful method of nicotine intake but in a different way. Any nicotine company like Altria, PMI, Bat or Swedish Match etc could still decide to invest a game changing amount of money into Lexaria at any time. The fact that they haven't yet is not any proof they won't.
Altria has just mentioned in this latest deal that they now have a couple of billion dollars of which they could allocate more towards their "Moving Beyond Smoking" line of products of which some of that money may hopefully find it's way into Lexaria's coffers. Altria also happens to be testing DehydraTECH on an ongoing basis. We are also starting a study within a couple of weeks to compare DehydraTECH pouches to leading nicotine pouches from Altria and Sweedish Match. Things could be changing for us in the near future. Good luck to all longs!
Thanks Shawking. The waiting sucks.
Also, it seems Chris bought 38,500 shares yesterday according to this Sedar Document. https://ir.lexariabioscience.com/sec-filings/all-sec-filings##document-1768-0001855763-22-000019-2
Hypertension study H21-4 dosing complete w/ no serious adverse affects https://ir.lexariabioscience.com/news-events/press-releases/detail/186/lexarias-dehydratech-cbd-hypertension-study-hyper-h21-4
Lexaria licensee Premier's new product launch https://www.marketscreener.com/quote/stock/PREMIER-ANTI-AGING-CO-L-119074088/news/Premier-Anti-Aging-Co-Ltd-146-s-Consolidated-Subsidiary-Premier-Wellness-Sciences-Co-Ltd-Anno-40920983/?utm_campaign=promo+202102+share_article++en_us&utm_source=twitter&utm_medium=display
Good point. The samples would have to have no contaminants whatsoever.
Nine major academic papers should get some attention :)
maybe Cannadips lol
Great find. Results should be very interesting for this one as this is basically the same main study that will be done in Phase 1 clinical trials coming soon.
Cannadips international expansion news https://ir.lexariabioscience.com/news-events/press-releases/detail/182/cannadips-is-expanding-intern
Lexaria, a global innovator in drug delivery platforms is pleased to announce that its DehydraTECH licensee Boldt Runners Corporation, owners of the Cannadips Brand, has expanded manufacturing agreements to include Europe, Japan, and South Africa.
If you shorted the stock at $2 you'd be hurting right now too! Seems just as pointless to mention...just saying.
Premier very likely has huge plans for DehydraTECH if Lexaria expects such huge royalty revenues. I didn't say what I thought was reasonable or not. Don't shoot the messenger!
Bevnology is the Research and Development arm of the larger company Intercontinental Beverage Capital with as near as I can see 25 employees and $5M rev.
https://www.zoominfo.com/c/intercontinental-beverage-capital-inc/358937538
https://inbevcapital.com/about/
https://ir.lexariabioscience.com/news-events/press-releases/detail/181/lexaria-signs-manufacturing-and-license-agreements-with
It appears IBC has offices and connections globally that help Food and Beverage companies with all the issues that pertain to successfully launching new products. Seems to be a useful partner to have IMO. https://inbevcapital.com/contact/
To clarify...A deal with Altria would help LEXX!
WSJ reports FDA to order Juul e cigarettes off US market. https://www.wsj.com/articles/fda-to-order-juul-e-cigarettes-off-u-s-market-11655904689
Maybe this could help LEXX get a deal with them.
PODA vote today for sale to Altria. https://poda-holdings.com/wp-content/uploads/2022/05/Management-Information-Circular-English.pdf
Lucky folks could make some money back!
The deal with Premier gives them right of first refusal for these areas.
"In order to encourage the expansion of DehydraTECH-enhanced Products within Asia, Premier has also been provided with a right of first refusal until May 20, 2025, to any license for the Technology in the nations of the People’s Republic of China and the Republic of Korea".
https://ir.lexariabioscience.com/sec-filings/all-sec-filings##document-1741-0001640334-22-001179-2
It says this right in the press release: "If Premier achieves even their worst-case projected penetration into the Japanese non-pharmaceutical CBD market, then based on their projections Lexaria could expect to receive annual payments of over $5 million by the fifth year of the contract."
It's not in the negotiated part!
Also, the huge multi million dollar revenues of the parent company could be very meaningful going forward. Better than making deals with broke companies with no revenue!
The deal with Japan's Premier Wellness is expected to pay Lexaria at least $5M per year by the fifth year of the contract. A bit more than a shell type!
"Premier's Parent had revenues of approximately US$187,000,000 in the first three quarters of fiscal 2021 with year-over-year revenue growth of 63.1% and strong profit margins. Parent sells over 45 product SKU's across four brands, and these products are sold in more than 16,000 retail stores as well as directly through mail/web order to over 2.6 million proprietary members. The overall Japanese cosmetics and personal products markets are estimated to be more than US$35 billion in annual sales". https://ir.lexariabioscience.com/news-events/press-releases/detail/178/lexaria-grants-exclusive-license-to-premier-wellness
But agreed that "big boy" contracts are welcome!
IMO the implication was passive aggressive. Why beat around the bush with this..."I think such and such". Posters should say what they mean instead of letting it be open to interpretation.
Lexaria has overhead costs...OMG. What kind of business are they running?!!! lol